AI and Medical Technology company ECHOIQ Limited (ASX:EIQ) has confirmed that research and findings underpinning the company’s latest AI-algorithm have been presented as late-breaking science at the world’s foremost cardiology conference, the European Society of Cardiology (ESC) Congress, in Barcelona, Spain.
Professor Geoffrey Strange from the University of Notre Dame, and also the Echo IQ Chief Strategy and Research Officer, presented the research “AI-Enhanced Detection of Aortic Stenosis” to leading researchers, scientists, commercial leaders and journalists from the cardiology, echocardiography and wider bio-technology sectors.
This work has been a collaboration between Professor Strange and Professor David Playford (University of Notre Dame and also Echo IQ’s Chief Medical Advisor) as well as the Company’s Technical Director Rakesh Patel and Data Scientist Dr. Andrew Watts.
Results from the AI-Enhanced Aortic Stenosis (AS) study show not only that AI can be used to identify individuals with guideline severe AS, but also an additional group with high risk of dying that may be missed by conventional definitions.
“The findings suggest that the AI algorithm could be used in clinical practice to alert physicians to patients who should undergo further investigations to determine if they qualify for aortic valve replacement,” Professor Strange commented.
“Given the rising prevalence of AS and its impact on mortality, it is time to revisit the practice of watchful waiting and consider more proactive attempts to identify those at risk.”
Echo IQ Achieves SOC 2 Compliance
Echo IQ is also pleased to announce a further step in its development with the successful completion of its System and Organisation Controls (SOC) 2 Type 1 audit, achieving compliance with the leading industry standards for customer data security.
This important milestone demonstrates Echo IQ’s commitment to providing a secure data environment for its customers. SOC 2 has a rigorous requirement on how companies handle customer data and information, and compliance guarantees there are established and implemented organisational practices in place to safeguard customer data.
Being accepted as a late-breaker at the ESC Congress is further evidence of the ground-breaking work we are bringing to the cardiology market,” Executive Chair Andrew Grover said.
“The research shared by our Chief Research and Strategy Officer underpins the Echo IQ solution, MyEcho Insight for which we are seeking FDA clearance, expected to be completed in early 2023. Completing a SOC 2 Type 1 independent audit provides clients with third-party assurance that we do more than talk about privacy. We are willing and able to provide independent testing and validation that proves our systems and controls for handling customer data can be trusted.”
